Phase I Study of AT13148, a Novel AGC Kinase Inhibitor

Summary

The purpose of this first clinical study of the noval multiple AGC kinase inhibitor, AT13148, is to identify the recommended dose for future studies in cancer patients by exploring the safety and maximum tolerated dose and biological effects in patients with advanced solid tumours.

Timeline

Start

2012-05

Primary completion

2018-01-10

Completion

2018-01-10

Drugs

Indications